JBIO News & Events

Jade Biosciences announced the first participant has been dosed in a first-in-human Phase 1 clinical trial of JADE201. JADE201 is an investigational, half-life extended, afucosylated monoclonal antibody targeting the B cell activating factor receptor designed to deplete B cells through a dual mechanism of action: enhanced antibody effector function and BAFF signal blockade. The company expects interim data in 2027.

Jade Biosciences announced that the first participant has been dosed in Juniper, the Company's Phase 2 trial evaluating JADE101 in participants with immunoglobulin A nephropathy. JADE101 is designed with high binding affinity to selectively block APRIL, a key driver of pathogenic IgA production in IgAN, a chronic autoimmune disease that frequently affects young adults and can lead to end-stage kidney disease over a patient's lifetime. Interim data from JUNIPER are expected in 2027.